Advertisement

Pharmaceutical Research

, 36:35 | Cite as

Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy

  • Peter Bloomingdale
  • Donald E. MagerEmail author
Research Paper
  • 158 Downloads

Abstract

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse side effect of cancer chemotherapy that can be life debilitating and cause extreme pain. The multifactorial and poorly understood mechanisms of toxicity have impeded the identification of novel treatment strategies. Computational models of drug neurotoxicity could be implemented in early drug discovery to screen for high-risk compounds and select safer drug candidates for further development.

Methods

Quantitative-structure toxicity relationship (QSTR) models were developed to predict the incidence of PN. A manually curated library of 95 approved drugs were used to develop the model. Molecular descriptors sensitive to the incidence of PN were identified to provide insights into structural modifications to reduce neurotoxicity. The incidence of PN was predicted for 60 antineoplastic drug candidates currently under clinical investigation.

Results

The number of aromatic nitrogens was identified as the most important molecular descriptor. The chemical transformation of aromatic nitrogens to carbons reduced the predicted PN incidence of bortezomib from 32.3% to 21.1%. Antineoplastic drug candidates were categorized into three groups (high, medium, low) based on their predicted PN incidence.

Conclusions

QSTR models were developed to link physicochemical descriptors of compounds with PN incidence, which can be utilized during drug candidate selection to reduce neurotoxicity.

Keywords

ADMET predictor chemotherapy-induced peripheral neuropathy machine learning toxicity QSAR 

Abbreviations

ADMET

Absorption, distribution, metabolism, excretion, and toxicity

ANN

Artificial neural network

CTCAE

Common terminology criteria for adverse events

CIPN

Chemotherapy-induced peripheral neuropathy

EORTC

European Organization for Research and Treatment of Cancer

EMA

European Medicines Agency

FDA

Food and Drug Administration

NCI

National Cancer Institute

PK/PD

Pharmacokinetic and pharmacodynamic

PN

Peripheral neuropathy

QLQ-CIPN20

Quality of Life Questionnaire-CIPN20

QSAR

Quantitative structure-activity relationship

QSTR

Quantitative-structure toxicity relationship

SVM

Support vector machine

Notes

Acknowledgments and Disclosures

We would like to thank Simulations Plus, Inc. for providing us with an academic license for ADMET Predictor™, ADMET Modeler™, and MedChem Designer™. Additionally, we would like to acknowledge Dr. Michael Lawless, Senior Principle Scientist at Simulations Plus, for his insightful suggestions throughout this project.

Supplementary material

11095_2018_2562_MOESM1_ESM.docx (343 kb)
Supplementary Figure 1 Molecular descriptor frequency and sensitivity of individual models (a) ANN non-transformed, (b) ANN log-transformed, (c) SVM 2% cutoff, and (d) SVM 10% cutoff of the individual models. (DOCX 342 kb)
11095_2018_2562_MOESM2_ESM.xlsx (15 kb)
Supplementary Table I (XLSX 14 kb)
11095_2018_2562_MOESM3_ESM.xlsx (22 kb)
Supplementary Table II (XLSX 22 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefGoogle Scholar
  2. 2.
    Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the "silver tsunami": prevalence trajectories and comorbidity burden among older Cancer survivors in the United States. Cancer Epidemiol Biomark Prev. 2016;25(7):1029–36.CrossRefGoogle Scholar
  3. 3.
    Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249(1):9–17.CrossRefGoogle Scholar
  4. 4.
    Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, et al. Chemotherapy-induced neuropathy in Cancer survivors. J Pain Symptom Manag. 2017;54(2):204–18 e202.CrossRefGoogle Scholar
  5. 5.
    Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507–15.CrossRefGoogle Scholar
  6. 6.
    Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012;291(1–3):1–9.CrossRefGoogle Scholar
  7. 7.
    Carozzi V, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms? Neurosci Lett. 2015;596:90–107.CrossRefGoogle Scholar
  8. 8.
    Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017.Google Scholar
  9. 9.
    Duch W, Swaminathan K, Meller J. Artificial intelligence approaches for rational drug design and discovery. Curr Pharm Des. 2007;13(14):1497–508.CrossRefGoogle Scholar
  10. 10.
    Burbidge R, Trotter M, Buxton B, Holden S. Drug design by machine learning: support vector machines for pharmaceutical data analysis. Comput Chem. 2001;26(1):5–14.CrossRefGoogle Scholar
  11. 11.
    Zhang L, Tan J, Han D, Zhu H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discov Today. 2017;22(11):1680–5.CrossRefGoogle Scholar
  12. 12.
    Council NR. Toxicity testing in the 21st century: a vision and a strategy: National Academies Press; 2007.Google Scholar
  13. 13.
    Raies AB, Bajic VB. In silico toxicology: computational methods for the prediction of chemical toxicity. Wiley Interdiscip Rev Comput Mol Sci. 2016;6(2):147–72.CrossRefGoogle Scholar
  14. 14.
    Bloomingdale P, Housand C, Apgar JF, Millard BL, Mager DE, Burke JM, et al. Quantitative systems toxicology. Curr Opin Toxicol. 2017;4:79–87.CrossRefGoogle Scholar
  15. 15.
    van de Waterbeemd H. Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003;2(3):192–204.PubMedGoogle Scholar
  16. 16.
    Mager DE. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev. 2006;58(12–13):1326–56.CrossRefGoogle Scholar
  17. 17.
    Moroy G, Martiny VY, Vayer P, Villoutreix BO, Miteva MA. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov Today. 2012;17(1–2):44–55.CrossRefGoogle Scholar
  18. 18.
    Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475–86.CrossRefGoogle Scholar
  19. 19.
    Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N, et al. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the critical path initiative. Am Heart J. 2009;158(3):317–26.CrossRefGoogle Scholar
  20. 20.
    Mager PP. Structure-neurotoxicity relationships applied to organophosphorus pesticides. Toxicol Lett. 1982;11(1–2):67–71.CrossRefGoogle Scholar
  21. 21.
    Cronin MT. Quantitative structure-activity relationship (QSAR) analysis of the acute sublethal neurotoxicity of solvents. Toxicol in Vitro. 1996;10(2):103–10.CrossRefGoogle Scholar
  22. 22.
    Makhaeva GF, Radchenko EV, Baskin II, Palyulin VA, Richardson RJ, Zefirov NS. Combined QSAR studies of inhibitor properties of O-phosphorylated oximes toward serine esterases involved in neurotoxicity, drug metabolism and Alzheimer's disease. SAR QSAR Environ Res. 2012;23(7–8):627–47.CrossRefGoogle Scholar
  23. 23.
    Estrada E, Molina E, Uriarte E. Quantitative structure-toxicity relationships using TOPS-MODE. 2. Neurotoxicity of a non-congeneric series of solvents. SAR QSAR Environ Res. 2001;12(5):445–59.CrossRefGoogle Scholar
  24. 24.
    Hur J, Guo AY, Loh WY, Feldman EL, Bai JP. Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy. CPT Pharmacometrics Syst Pharmacol. 2014;3:e114.CrossRefGoogle Scholar
  25. 25.
    Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy: review of the literature. Pharmacotherapy. 2004;24(9):1194–203.CrossRefGoogle Scholar
  26. 26.
    Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology. 2014;83(14):1261–3.CrossRefGoogle Scholar
  27. 27.
    J-I A. Reduced HOMO− LUMO gap as an index of kinetic stability for polycyclic aromatic hydrocarbons. J Phys Chem A. 1999;103(37):7487–95.CrossRefGoogle Scholar
  28. 28.
    Duraiswamy AJ, Lee MA, Madan B, Ang SH, Tan ES, Cheong WW, et al. Discovery and optimization of a porcupine inhibitor. J Med Chem. 2015;58(15):5889–99.CrossRefGoogle Scholar
  29. 29.
    Gramatica P, Sangion A. A historical excursus on the statistical validation parameters for QSAR models: a clarification concerning metrics and terminology. J Chem Inf Model. 2016;56(6):1127–31.CrossRefGoogle Scholar
  30. 30.
    Reed AE, Weinstock RB, Weinhold F. Natural population analysis. J Chem Phys. 1985;83(2):735–46.CrossRefGoogle Scholar
  31. 31.
    Hajduk PJ, Sauer DR. Statistical analysis of the effects of common chemical substituents on ligand potency. J Med Chem. 2008;51(3):553–64.CrossRefGoogle Scholar
  32. 32.
    Pennington LD, Moustakas DT. The necessary nitrogen atom: a versatile high-impact design element for multiparameter optimization. J Med Chem. 2017;60(9):3552–79.CrossRefGoogle Scholar
  33. 33.
    Fukui K, Yonezawa T, Shingu H. A molecular orbital theory of reactivity in aromatic hydrocarbons. J Chem Phys. 1952;20(4):722–5.CrossRefGoogle Scholar
  34. 34.
    Pearson RG. Absolute electronegativity and hardness correlated with molecular orbital theory. Proc Natl Acad Sci. 1986;83(22):8440–1.CrossRefGoogle Scholar
  35. 35.
    Traquandi G, Ciomei M, Ballinari D, Casale E, Colombo N, Croci V, et al. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors. J Med Chem. 2010;53(5):2171–87.CrossRefGoogle Scholar
  36. 36.
    Scully SS, Tang AJ, Lundh M, Mosher CM, Perkins KM, Wagner BK. Small-molecule inhibitors of cytokine-mediated STAT1 signal transduction in beta-cells with improved aqueous solubility. J Med Chem. 2013;56(10):4125–9.CrossRefGoogle Scholar
  37. 37.
    Hong SP, Liu KG, Ma G, Sabio M, Uberti MA, Bacolod MD, et al. Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem. 2011;54(14):5070–81.CrossRefGoogle Scholar
  38. 38.
    Pennington LD, Croghan MD, Sham KK, Pickrell AJ, Harrington PE, Frohn MJ, et al. Quinolinone-based agonists of S1P(1): use of a N-scan SAR strategy to optimize in vitro and in vivo activity. Bioorg Med Chem Lett. 2012;22(1):527–31.CrossRefGoogle Scholar
  39. 39.
    Yuan Y, Zaidi SA, Elbegdorj O, Aschenbach LC, Li G, Stevens DL, et al. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity. J Med Chem. 2013;56(22):9156–69.CrossRefGoogle Scholar
  40. 40.
    Borrmann T, Abdelrahman A, Volpini R, Lambertucci C, Alksnis E, Gorzalka S, et al. Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. J Med Chem. 2009;52(19):5974–89.CrossRefGoogle Scholar
  41. 41.
    Zheng X, Bauer P, Baumeister T, Buckmelter AJ, Caligiuri M, Clodfelter KH, et al. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors. J Med Chem. 2013;56(12):4921–37.CrossRefGoogle Scholar
  42. 42.
    Bregman H, Nguyen HN, Feric E, Ligutti J, Liu D, McDermott JS, et al. The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR. Bioorg Med Chem Lett. 2012;22(5):2033–42.CrossRefGoogle Scholar
  43. 43.
    Horne DB, Tamayo NA, Bartberger MD, Bo Y, Clarine J, Davis CD, et al. Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists. J Med Chem. 2014;57(7):2989–3004.CrossRefGoogle Scholar
  44. 44.
    Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, Tran TD. Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem. 2010;53(24):8441–60.CrossRefGoogle Scholar
  45. 45.
    Kundu TK, Velayutham M, Zweier JL. Aldehyde oxidase functions as a superoxide generating NADH oxidase: an important redox regulated pathway of cellular oxygen radical formation. Biochemistry. 2012;51(13):2930–9.CrossRefGoogle Scholar
  46. 46.
    Li H, Kundu TK, Zweier JL. Characterization of the magnitude and mechanism of aldehyde oxidase-mediated nitric oxide production from nitrite. J Biol Chem. 2009;284(49):33850–8.CrossRefGoogle Scholar
  47. 47.
    Areti A, Yerra VG, Naidu V, Kumar A. Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox Biol. 2014;2:289–95.CrossRefGoogle Scholar
  48. 48.
    Diamond S, Boer J, Maduskuie TP Jr, Falahatpisheh N, Li Y, Yeleswaram S. Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos. 2010;38(8):1277–85.CrossRefGoogle Scholar
  49. 49.
    Uetrecht J. N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab Rev. 2002;34(3):651–65.CrossRefGoogle Scholar
  50. 50.
    Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000;356(9241):1587–91.CrossRefGoogle Scholar
  51. 51.
    Sodhi JK, Wong S, Kirkpatrick DS, Liu L, Khojasteh SC, Hop CE, et al. A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos. 2015;43(6):908–15.CrossRefGoogle Scholar
  52. 52.
    Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, et al. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leuk Lymphoma. 2017;58(8):1872–9.CrossRefGoogle Scholar
  53. 53.
    Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3–9.CrossRefGoogle Scholar
  54. 54.
    Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev. 2006;11(4):294–329.PubMedGoogle Scholar
  55. 55.
    Kamerman PR, Moss PJ, Weber J, Wallace VC, Rice AS, Huang W. Pathogenesis of HIV-associated sensory neuropathy: evidence from in vivo and in vitro experimental models. J Peripher Nerv Syst. 2012;17(1):19–31.CrossRefGoogle Scholar
  56. 56.
    Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998;9(7):739–44.CrossRefGoogle Scholar
  57. 57.
    Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46(3):479–94.CrossRefGoogle Scholar
  58. 58.
    Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother. 2001;35(12):1540–7.CrossRefGoogle Scholar
  59. 59.
    Tierney EF, Thurman DJ, Beckles GL, Cadwell BL. Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older. J Diabetes. 2013;5(2):207–15.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical SciencesUniversity at Buffalo, The State University of New YorkBuffaloUSA

Personalised recommendations